Institut National De La Sante Et De La Recherche Medicale

Baylor Research Institute

Université Paris Est Creteil Val De Marne

Assistance Publique-hopitaux De Paris

Centre National De La Recherche Scientifique

Assistance Publique - Hopitaux De Paris (aphp)

Commissariat a L'energie Atomique

Institut D'optique Theorique Et Appliquee

Agence Nationale De Recherches Sur Le Sida Et Les Hepatitis Virales

Inserm (institut National De La Sante Et De La Recherche Medicale)

Inserm

Yves Levy

Gerard Zurawski

Anne-Laure Flamar

Jacques F Banchereau

Monica Montes

Sandra M Zurawski

Armand Bensussan

Jean-Francois Eliaou

Sophie Hue

Nathalie Bonnefoy-Berard

Jean-Daniel Lelievre

Thierry Livache

Anna Karolina Palucka

Jean-Gérard Guillet

Andre Roget

Jean-Marc Balloul

Inna Menkova-Garnier

Doris Schmitt

Philippe Guedon

Helene Dutartre

Louis M Sloan

Jean-François Eliaou

The invention relates to antibodies against human CD39 and use thereof for inhibiting T regulatory cells (Treg) activity. More particularly CD39 antibodies may be used for the treatment or prevention of cancers and infectious diseases.

Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity

Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).

Methods and compositions for treating and preventing HIV

The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

Fusion proteins comprising an anti-CD40 antibody and HIV antigenic peptides

The invention provides diagnostic markers of immunosenescence and methods of identifying individuals with impaired immune function based on the expression level of a combination of such markers in a biological sample obtained from said individual. Such combination of markers is useful for determining the susceptibility to nosocomial infections of an individual. Such combination of markers is also useful for predicting whether an individual will respond to active vaccination and become protected against recurring diseases.

Diagnostic markers of immunosenescence and methods for determining the susceptibility to nosocomial infections

The present invention relates to pharmaceutical composition and uses thereof for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV). In particular, the present invention relates to a P2X7 receptor antagonist for use in a method of restoring T-cell lymphopoiesis in a subject infected with human immunodeficiency virus (HIV) comprising administering to the subject a therapeutically effective amount of said P2X7 receptor antagonist.

P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV)

Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C.

Compositions and methods to immunize against hepatitis C virus

Compositions and methods for the prophylaxis and treatment of human immunodeficiency virus (HIV) infections are disclosed herein. More specifically the present invention discloses describes an autologous dendritic cell (DC) vaccine product derived by culturing a patient's monocytes with granulocyte macrophage colony stimulating factor (GM-CSF) and interferon alpha 2b (IFN-&#x3b1;), loading the DC with a mixture of five lipopeptides of Gag, Nef and Pol HIV antigens, and, optionally activating the DC with lipopolysaccharide (LPS).

Dendritic cell vaccines

The present invention relates to materials and methods concerning the IL-1 receptor family protein ST2. Use of soluble ST2 as a marker for cardiovascular disease or disease outcome is provided, in particular as a marker of the risk of mortality.

Soluble ST2 as a marker for risk of mortality in HIV-infected subjects

Antigen presenting cell targeted anti-viral vaccines

Anti-CD40 targeted fusion proteins

The invention relates to a synthetic gene coding for the Gag protein of the human immunodeficiency virus HIV-1. Said gene may optionally be fused with one or more other HIV sequences. The invention may notably be used within the scope of obtaining anti-HIV vaccines.

Synthetic gene construct coding for an HIV1 GAG and use thereof for obtaining anti-HIV-1 vaccines

Fusion protein with HIV antigen

Growing community of inventors

Paris, France

Yves Levy